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We conducted a cross-sectional, hospital-based study between January 2006-March 2008 to estimate the re-
sistance of Mycobacterium tuberculosis to first-line drugs in patients with tuberculosis at a Brazilian hospital. We 
evaluated the performance of the [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide] (MTT) microplate 
assay compared with the Bactec-MGIT 960™ system for mycobacteria testing. The prevalence of resistance in M. 
tuberculosis was 6.7%. Multidrug-resistance [resistance to rifampicin (RMP) and isoniazid (INH)], INH-resistance 
and streptomycin (SM)-resistance accounted for 1%, 3.8% and 3.8% of all resistance, respectively, and all isolates 
were susceptible to ethambutol (EM). The resistance was primary in four cases and acquired in three cases and 
previous treatment was associated with resistance (p = 0.0129). Among the 119 M. tuberculosis isolates, complete 
concordance of the results for INH and EM was observed between the MTT microplate and Bactec-MGIT 960™ 
methods. The observed agreement for RMP was 99% (sensitivity: 90%) and 95.8% for SM (sensitivity 90.9%), lower 
than those for other drugs. The MTT colourimetric method is an accurate, simple and low-cost alternative in settings 
with limited resources. 
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Mycobacterium tuberculosis multidrug resistance 
(MDR) is an emerging global problem. The World 
Health Organization has estimated that 14% of all new 
tuberculosis (TB) cases involve MDR (WHO 2008). In 
the last decade, MDR-TB was observed in 0.9% of new 
Brazilian cases diagnosed in primary health care units 
(Natal et al. 1997). However, according to the Brazilian 
Ministry of Health Program, this epidemiological trend 
is changing: recent data indicate increased resistance 
and the initial standard treatment regimen now includes 
four drugs (MS/SVS 2009). 
Early detection of M. tuberculosis resistance is a 
concern at local and international levels, especially for 
health care facilities in metropolitan areas with high 
population densities, high human immunodeficiency 
virus (HIV) infection rates and large numbers of insti-
tutionalized and homeless people. New drug suscepti-
bility tests (DST) must be developed and implemented 
that are accurate enough to identify drug resistance, but 
that are also low-cost, sustainable and accessible. Many 
DSTs have attempted to meet these requirements and 
colorimetric assays have been proposed as cost-effec-
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tive alternatives to high-cost, automated phenotyping 
and genotyping methods. Colorimetric methods us-
ing alamarBlue, resazurin or 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) reveal 
cellular viability in the presence of variable drug con-
centrations and allow the determination of the drugs’ 
minimum inhibitory concentration (MIC) (Franzblau 
et al. 1998, Palomino & Portaels 1999, Caviedes et al. 
2002, Ribeiro et al. 2004).
In this study, we tested TB patients at a Brazilian 
hospital to estimate the prevalence of resistance of M. 
tuberculosis to first-line drugs and to evaluate the per-
formance of the MTT microplate assay compared with 
Bactec-MGIT 960™. 
PATIENTS, MATERIALS AND METHODS
A retrospective, cross-sectional study was performed 
at a Brazilian tertiary health-care facility in the Campi-
nas metropolitan area, a region with a population of five 
million and a recent TB incidence rate of 48 per 100,000 
inhabitants. We defined two study groups: the preva-
lence study group (P-group) and the MTT performance 
evaluation group (MTT-group). The P-group included 
patients of at least 14 years of age with a positive M. tu-
berculosis culture diagnosis reported to the surveillance 
system between January 2006-March 2008. To select the 
P-group, we evaluated 360 cases that were reported to 
the surveillance system and included 105 patients. The 
MTT-group was composed of all of the patients in the 
P-group and an additional 14 cases with confirmed re-
sistance to first-line drugs prior to the study. 
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The drug susceptibility patterns of M. tuberculosis 
were tested using the MTT assay and Bactec-MGIT 
960™. Reference susceptibility patterns were obtained 
from Bactec-MGIT 960™ performed by Mycobacteriol-
ogy Division of the Adolfo Lutz Institute, the regional 
laboratory of the state of São Paulo (SP). The MTT assay 
was performed at the Mycobacteriology Laboratory, Di-
vision of Clinical Pathology, State University of Campi-
nas (UNICAMP) according to Franzblau et al. (1998) for 
the following drugs: isoniazid (INH), rifampicin (RMP), 
ethambutol (EM) and streptomycin (SM). M. tubercu-
losis suspensions were prepared by inoculating colonies 
from slants into 2 mL of 7H9 broth (Sigma Chemical Co, 
St. Louis, MO, USA) and incubating at 37ºC for seven 
days. The turbidity was adjusted to McFarland Standard 
3 by adding Middlebrook 7H9. Middlebrook 7H9 was 
prepared with 0.47 g of 7H9 broth base (Difco, Detroit, 
MI, USA), 0.2 mL of glycerol, 90 mL of distilled water 
and 10 mL of a mixture of oleic acid, albumin, dextrose 
and catalase (OADC) (Becton-Dickinson). RMP and 
INH stock solutions (10 mg/mL) were prepared in meth-
anol and water, respectively. EM stock solutions were 
prepared in distilled water with and without 20% ethanol 
and SM solutions were prepared in distilled water with 
and without 5% phenol. 
Microdilution plates were prepared by adding 200 µL 
of sterile water to all outer wells and 100 µL of 7H9 
broth to columns 2-11 in rows B-G. Then, 100 µL of 
4x antibiotic solutions (INH, RMP, SM or EM) were 
added to rows B-G of column 2. To perform the dilution, 
100 µL were transferred from row B-G of column 2 to 
column 3 with a multi-channel pipette. The antibiotics 
were serially diluted 1:2 in this manner except in column 
11, where the 100 µL of excess media was discarded. 
The final drug concentration ranges were 0.015-16 µg/mL 
for INH, 0.015-16 µg/mL for RMP, 0.01-16 µg/mL for 
SM and 0.03-16 µg/mL for EM. At this point, 100 µL 
of a log-phase M. tuberculosis bacterial suspension (20-
30 days old) were added to rows B-G in columns 2-11. 
Bacteria were not added to row H of columns 10 and 11 
and these wells served as inoculum controls. The plates 
were sealed with parafilm in plastic bags and incubated 
at 37°C for six or seven days. On day six, 15 µL of 5 mg/mL 
MTT (Sigma-Aldrich) in a 1:9 ratio of ethanol:water was 
added to well H10. The plate was incubated at 37°C for 
24 h and, if the color of H10 turned purple, MTT was 
added to all wells and the color was recorded at 24 h. If 
the color of well H10 remained yellow, the plates were 
incubated for another 24 h. At this point, MTT solution 
was added to well H11 and the plate was incubated for 
another 24 h to observe the color change. Isolates were 
considered to be drug susceptible if their MICs were be-
low or equal to the critical concentrations reported by 
Martin et al. (2005): INH, 0.25 µg/mL; RMP, 0.5 µg/mL; 
EM, 4 µg/mL; SM, 1 µg/mL. The critical concentra-
tions of Bactec-MGIT 960™ reported by the manufac-
turer’s protocol were as follows: INH, 0.10 µg/mL; RMP, 
1.0 µg/mL; EM, 5.0 µg/mL; SM, 1.0 µg/mL. 
Statistical analysis was performed with Epi-Info ver-
sion 6.04b (Centers for Disease Control and Prevention, 
Atlanta, GA, USA). Categorical variables were analyzed 
with Chi-square (Yates’ correction) and two-tailed Fisher’s 
exact tests. P values of < 0.05 were considered statistically 
significant. The study was approved by the Ethical Com-
mittee of the Faculty of Medical Sciences of UNICAMP. 
RESULTS
Among the 105 P-group patients, 78 (74.3%) were 
male and the median age was 36 years. Pulmonary pre-
sentation alone was observed in 68 (64.8%) cases, ex-
tra-pulmonary in 11 (10.5%) cases and combined (pul-
monary and extra-pulmonary) in 26 (24.7%) patients. 
Disseminated disease occurred in seven (18.9%) cases. 
Thoracic x-rays were suggestive of TB in 82 (78.1%) 
cases. Among the 94 (89.5%) patients with pulmonary 
involvement, 66 (62.9%) had sputum positive for acid-
fast bacilli and 82 (78.1%) had M. tuberculosis-positive 
sputum cultures. In other specimens, acid-fast bacilli 
were observed in 13 (12.4%) cases and the culture was 
positive in 39 (37.1%) cases. HIV co-infection was di-
agnosed in 39 (37.1%) cases. Of the 10 patients that had 
previous treatment, six (5.7%) were cured, three (2.8%) 
were in default of treatment and one case failed.
The prevalence of drug-resistant M. tuberculosis was 
6.7%, MDR was detected in a single case and resistance 
to INH and SM was detected in 3.8% of cases (Table I). 
The resistance was primary in four cases and acquired in 
three. Previous treatment was associated with resistance 
(p = 0.0129); however, HIV was not related to resistance. 
Favorable treatment outcomes occurred in 67 (63.8%) 
cases, death in 26 (24.8%) cases and default of treatment 
in 12 (11.4%) cases. Of the seven patients with drug-re-
sistance, four were cured, two died and follow-up data 
was not available for one. The patient with MDR-TB was 
cured at the 18th month of the treatment. 
Analysis of the MTT-group (119 M. tuberculosis iso-
lates) showed agreement between the MTT and Bactec-
MGIT 960™ methods in 100% of cases for INH and EM, 
99% for RMP and 95.8% for SM (Table II). Final results 
(resistant or susceptible) were similar when ethanol or 
phenol was added to solubilise EM or SM, respectively.
TABLE I
Prevalence of resistance to first-line antimycobacterial agents 
among tuberculosis cases in prevalence study group performed 
by MTT microplate assay and Bactec-MGIT 960™a
Drug
Resistant Susceptible
n = 7 % n = 98 %
Isoniazid 4 3.8 101 96.2
Rifampicin 1 1 104 99
Ethambutol 0 0 105 100
Streptomycin 4 3.8 101 96.2
Isoniazid + rifampicin 1 1 104 99
Total 7 6.7 98 93.3
a: the benchmark test when the results were discrepant; 
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium 
bromide assay.
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DISCUSSION
In our study, the presence of resistant-TB was lower 
than in other Brazilian studies performed at tertiary care 
facilities. Although few Brazilian hospital-based stud-
ies have specifically evaluated resistance, the resistance 
rates reported by other studies were higher. For RMP, 
INH or any drug, the resistance rates varied from 3.6-
4.3%, 10.9-13% and 13.3-19.2%, respectively (Brito et al. 
2004, de Souza et al. 2006, Aguiar et al. 2009). Our re-
sults can be explained by the characteristics of our study 
population, such as the number of cases evaluated, the 
absence of previous treatment in the majority of patients 
and the TB incidence rate in the Campinas metropolitan 
area being lower than in Rio de Janeiro, where most Bra-
zilian studies have been conducted.
MDR-TB has been evaluated in other Brazilian hos-
pitals at higher rates than observed in the general popu-
lation. In the 1990s, a national surveillance of resistance 
in basic health care units reported that 0.9% of cases 
were MDR-TB and 8.6% of all cases were resistant to 
some drug. Similar results were observed in SP (Pablos-
Méndez et al. 1998, Telles et al. 2005). 
An association between resistance and previous treat-
ment was found in our study, as well as in other studies 
(Fandinho et al. 1999, de Melo et al. 2003, Aguiar et al. 
2009). In Brazil, acquired resistance was related to in-
adequate adherence to treatment, supporting the move-
ment to extend directly observed therapy. 
The general performance of the MTT microplate as-
say was adequate to detect resistance to INH, RMP and 
EM. The assay results were in agreement with Bactec-
MGIT 960™, but few TB resistance isolates were tested. 
These results are compatible with results reported by 
others (WHO 1997, Palomino & Portaels 1999, Caviedes 
et al. 2002, Ribeiro et al. 2004, Mengatto et al. 2006). 
DST for EM and SM has been reported to have low re-
producibility (WHO 1997). In a multicentric study of the 
MTT assay, Martin et al. (2005) reported specificity and 
sensitivity for SM of 85% and 90.5%, respectively. These 
results are probably associated with the drug’s stability. 
In our study, we added ethanol in small concentrations 
to improve the stability of EM in the stock solutions and 
phenol was added for SM solubility. This approach pos-
sibly improves the evaluation of EM and SM resistance 
through MTT evaluation. 
In addition, the MTT microplate assay has been 
widely used to test second-line antimycobacterial drugs. 
Expertise with this method assumes great importance in 
the context of the global rise in MDR, primarily in de-
veloping countries. 
Reported overall efficiencies of the MTT and resazur-
in assays have been similar with high accuracy, except for 
SM (Martin et al. 2005, Montoro et al. 2005). According to 
previous studies, MTT allows for a better interpretation of 
colors, which facilitates its standardization (Ribeiro et al. 
2004). One test for resistance to four drugs using MTT or 
resazurin costs $5 (US) or $3 (US), respectively, whereas 
the test performed by Bactec-MGIT 960™ costs $39 (US) 
(Mengatto et al. 2006, WHO 2008). The use of colorimet-
ric methods to detect drug resistance in M. tuberculosis 
has recently been endorsed by the Strategic and Technical 
Advisory Group for Tuberculosis (WHO 2009).
The next steps to take towards standardizing the MTT 
and resazurin colorimetric tests for clinical evaluation 
depend on phases III (performance) and phase IV (cost-
effectiveness) clinical trials and involve comparisons with 
reference methods (Palomino et al. 2007). A study analyz-
ing the cost-effectiveness of five DST methods, including 
the MTT assay, was performed in Peru and they found 
that all of the methods to identify MDR-TB in middle-
income countries were cost-effective. Including the cost 
savings from reduced TB transmission, the MTT assay 
had the second-lowest gained cost per disability-adjusted 
life-year ($95 US) (Acuna-Villaorduna et al. 2008). New 
colorimetric methods now enable the direct diagnosis of 
resistance in clinical specimens (Pai et al. 2006).
The MTT colorimetric method is an accurate, sim-
ple test that costs less than the automated phenotyping 
and genotyping methodologies. Colorimetric tests are a 
boon for settings with limited resources and make pos-
sible sustainable resistance surveillance, a critical step 
in global TB control. 
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